[Therapy of atopic eczema with calcineurin inhibitors].
Luger
Thomas A
TA
Hautklinik, Universitätsklinikkum Münster, Deutschland. luger@uni-muenster.de
Bieber
Thomas
T
Meurer
Michael
M
Mrowietz
Ulrich
U
Schwarz
Thomas
T
Simon
Jan
J
Werfel
Thomas
T
Zuberbier
Torsten
T
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000465:Algorithms; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D018849:Controlled Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007223:Infant; D009824:Ointments; D017410:Practice Guidelines as Topic; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009824:Ointments; C117268:pimecrolimus; D016559:Tacrolimus